India’s Sun Pharmaceutical Industries Ltd said on Tuesday it would soon begin selling its version of favipiravir, becoming the latest generic drugmaker to supply the antiviral to treat COVID-19 in the world’s third worst-hit nation. Favipiravir, along with another antiviral, remdesivir, has emerged as one of the most sought-after drugs at hospitals fighting COVID-19 in India, which saw a surge of 50,000-plus infections for the sixth straight day on Tuesday. Sun’s version of favipiravir, to be called FluGuard, will cost 35 rupees (47 cents) per 200 mg tablet, making it the cheapest version available. Stocks will be available from this week. This and more in today’s Coronavirus Update. #SunPharma #Favipiravir #FluGuard
SUBSCRIBE to HW News English Here ►
Download the HW News Network free app available on Android and iOS:
For NEWS and POLITICAL updates in English. Send us a ‘Hi’ on our Whatsapp Number – 9820918578
#HWNewsEnglish #HwLatestNews
For advertising related queries write to us at sales@hwnews.in
Connect With Us On:
→ Facebook:
→ Twitter:
For More Videos Visit Here:
